Helibacter Pylori Infection
Conditions
Interventions
Group 1:Treatment of Helicobacter pylori infection: Group A: traditional bismuth quadruple, including esomeprazole (AstraZeneca, London, UK) 20 mg, twice a day
bismuth potassium citrate capsules (Livzon Group, Zhuhai, China) 220 mg, twice a day
amoxicillin capsules (United Pharmaceuticals, Zhuhai, China) 1000 mg, twice a day
clarithromycin capsules (Abbott Pharmaceuticals, Shanghai, China) 500 mg, twice a day
treatment course of 14 days.
Group 2:Group B: vonoprazan-amoxicillin dual combination, including amoxicillin capsules (United Pharmaceuticals, Zhuhai, China) 1000 mg, twice a day
vonoprazan fumarate tablets (Takeda Pharmaceuticals, Tokyo, Japan) 20 mg, twice a day, treatment course of 14 days.
Sponsors
Peking University International Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18-70 years, male or female; (2) Helicobacter pylori infection diagnosed by 13/14C-urea breath test (13/14C-UBT) or stool H pylori antigen detection or immunohistochemical staining of biopsy specimens; (3) Provided informed consent for participation in this study.
Exclusion criteria
Exclusion criteria: (1)No previous history of Hp eradication treatment;(2) History of taking antibiotics, bismuth, or traditional Chinese medicines with antibacterial effects within one month, and taking PPI, H2 receptor antagonists or other drugs that affect Hp activity within two weeks;(3) Serious diseases or clinical conditions such as liver disease, lung disease and cardiovascular disease;(4) Allergy to penicillin or other drugs used in this clinical trial;(5) Pregnancy or lactation;(6) Patients with severe gastrointestinal diseases, such as malignant tumors, gastrointestinal bleeding, or Zoe syndrome, after subtotal gastrectomy;(7) Patients who were assessed by the researcher and were not considered suitable for enrollment due to low compliance or safety reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| incidence rate of adverse reactions; | — |
Countries
China
Contacts
Public ContactFAN XUE
Peking University International Hospital
Outcome results
None listed